Application

New class of small molecule inhibitors with therapeutic potential for inflammatory diseases through disruption of the p38/MK2 protein-protein interaction.

Key Benefits

• Therapeutic potential and utility for various inflammatory diseases.
• May have potentially fewer off-target effects and dose-limiting toxicities.
• May serve as a foundation to further develop brain-penetrant anti-inflammatory agents.

Market Summary

Neuroinflammation is a major hallmark of multiple neurological disorders, including ALS, Parkinson's disease, and Alzheimer’s disease, the leading cause of dementia, affecting more than six million Americans aged 65 or older, with prevalence expected to rise. Current therapies targeting β-amyloid (Aβ) plaque clearance have shown limited clinical benefit, underscoring the need for alternative approaches. Chronic inflammation is a key driver of disease progression, positioning neuroinflammation as a promising therapeutic focus. However, existing small molecule strategies targeting pathways such as p38/MK2 have been ineffective, often due to broad activity across multiple binding partners that leads to poor tolerability, systemic toxicity, and low efficacy, resulting in repeated clinical trial failures. More broadly, despite a range of available anti-inflammatory treatments — including NSAIDs, monoclonal antibodies, JAK inhibitors, and TNF blockers — there are no effective and stable FDA-approved therapies that specifically target neuroinflammation. Anti-inflammatory drugs remain widely used to treat acute and chronic pain, with demand increasing alongside an aging population and rising rates of inflammatory diseases. Together, these dynamics highlight a significant unmet need for safer, more effective, and more targeted anti-inflammatory therapies with improved stability and reduced side effects.

Technical Summary

Researchers at Emory University have identified small molecules that can disrupt the p38/MK2 complex interface rather than the kinase active sites. The small molecule inhibitors keep the two proteins from interacting with each other by binding at the protein-protein interaction interface. Existing therapies targeting ATP binding on p38/MK2 have failed in clinical trials due to toxicity and poor tolerability. The proposed approach offers a targeted alternative that may overcome these limitations and is well-positioned to address gaps in current treatment options of neuroinflammatory diseases.

Development Stage

Over 1,000 compounds were screened, and further in vitro studies were conducted to validate therapeutic efficacy of 12 chosen compounds.